RecruitingPhase 4NCT05593653

Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes

Treating Insomnia and Improving Glycemic Control in Midlife Women With Insomnia and Pre-diabetes


Sponsor

Brigham and Women's Hospital

Enrollment

61 participants

Start Date

Jan 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia in midlife women who are pre-diabetic.


Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 65 Years

Inclusion Criteria7

  • Healthy women aged 40-65 years
  • Postmenopausal or late perimenopausal
  • Meets criteria for Insomnia Disorder
  • Score on the Insomnia Severity Index (ISI) measure ≥15
  • Subjective and sustained sleep disruption during screening
  • Hot flashes present, including at night
  • Pre-diabetic per guidelines from the American Diabetes Association

Exclusion Criteria23

  • Diagnosis of other primary sleep disorders
  • Shift worker
  • Frequent use of hypnotic medications
  • Unwillingness to refrain from taking any sleep medications during the study period
  • Current major depressive episode
  • Suicidal ideation
  • Lifetime history of bipolar disorder, psychosis, or other serious mental health problem
  • Current alcohol/substance use disorder
  • Current or prior diagnosis of diabetes mellitus
  • Use of an insulin sensitizer or a pharmacologic treatment for pre-diabetes
  • Extreme obesity
  • Current use of systemic hormonal therapies
  • Renal or hepatic disease
  • Pregnancy or breastfeeding
  • Recent malignancy
  • Recent surgery
  • Neurological disorder or cardiovascular disease raising safety concerns
  • Medical instability considered to interfere with study procedures
  • Concomitant medications with drug interaction or co-administration concerns
  • Contraindications or allergic responses to suvorexant
  • Recent travel across time zones
  • Excessive coffee or cigarette use
  • Unwilling to limit alcohol, nicotine, and caffeine consumption during study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSuvorexant

20mg taken at bedtime for 4 weeks

DRUGPlacebo

placebo taken at bedtime for 4 weeks


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05593653


Related Trials